FrancophonIA/ELRC3.0 huggingface dataset:
English: Descovy should be avoided in patients with estimated CrCl ≥ 15 mL/min and < 30 mL/min, or < 15 mL/min who are not on chronic haemodialysis, as the safety of Descovy has not been established in these populations.
Danish: Descovy anbefales ikke til patienter med en estimeret CrCl ≥ 15 ml/min og < 30 ml/min, eller < 15 ml/min, som ikke er i kronisk hæmodialyse, da Descovys sikkerhed hos disse populationer ikke er klarlagt.
English: No clinically relevant pharmacokinetic differences due to age, gender or ethnicity have been identified for emtricitabine, or tenofovir alafenamide.
Danish: Der er ikke blevet identificeret klinisk relevante farmakokinetiske forskelle på grund af alder, køn eller etnicitet for emtricitabin eller tenofoviralafenamid.
English: Tablet core: Microcrystalline cellulose, croscarmellose sodium, magnesium stearate.
Danish: Tabletkerne: Mikrokrystallinsk cellulose, croscarmellosenatrium, magnesiumstearat.
English: Cross-resistance in HIV-1 infected, treatment-naïve or virologically suppressed patients Emtricitabine-resistant viruses with the M184V/I substitution were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir, and zidovudine.
Danish: Krydsresistens hos hiv 1-inficerede, behandlingsnaive eller virologisk supprimerede patienter Emtricitabin-resistente vira med M184V/I-substitution var krydsresistente over for lamivudin, men havde bevaret følsomhed for didanosin, stavudin, tenofovir og zidovudin.
English: 30 film-coated tablets 90 (3 bottles of 30) film-coated tablets
Danish: 30 filmovertrukne tabletter 90 (3 beholdere med 30) filmovertrukne tabletter
English: No antagonism was observed with emtricitabine or tenofovir alafenamide when combined with other antiretroviral agents.
Danish: Ingen antagonisme med emtricitabin eller tenofoviralafenamid blev observeret ved kombination med andre antiretrovirale midler.
English: Following administration of food in healthy subjects, peak plasma concentrations were observed approximately 1 hour post-dose for tenofovir alafenamide administered as F/TAF (25 mg) or E/C/F/TAF (10 mg).
Danish: Efter administration af mad til raske personer blev maksimale plasmakoncentrationer observeret ca. 1 time efter dosering for tenofoviralafenamid, administreret som F/TAF (25 mg) eller E/C/F/TAF (10 mg).
English: Patients were virologically suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months before switching.
Danish: Patienterne var virologisk supprimerede (hiv 1-rna < 50 kopier/ml) i mindst 6 måneder, før de skiftede.
English: Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice.
Danish: Hos patienter med tidligere tilfælde af leverdysfunktion, herunder kronisk aktiv hepatitis, er der en forhøjet forekomst af unormal leverfunktion under antiretroviral kombinationsbehandling (CART, combination antiretroviral therapy), og disse patienter bør monitoreres i henhold til standardprocedurer.
English: Adolescents 12 years of age and older, who weigh at least 35 kg: one tablet each day with or without food Do not chew, crush or split the tablet.
Danish: Unge i alderen 12 år og ældre, som vejer mindst 35 kg: en tablet om dagen sammen med eller uden mad
English: Multinucleoside-resistant HIV-1 with a T69S double insertion mutation or with a Q151M mutation complex including K65R showed reduced susceptibility to tenofovir alafenamide.
Danish: Multinukleosid-resistent hiv 1 med en T69S dobbelt indsætningsmutation eller med et Q151M-mutationskompleks, der omfattede K65R, viste en nedsat følsomhed over for tenofoviralafenamid.
English: The proportions of patients with plasma HIV-1 RNA < 50 copies/mL and < 20 copies/mL are shown in Table 5.
Danish: Andelene af patienter med plasma hiv 1-rna < 50 kopier/ml og < 20 kopier/ml er vist i tabel 5.
English: If the patient vomits within 1 hour of taking Descovy another tablet should be taken.
Danish: Hvis patienten kaster op inden for 1 time efter at have taget Descovy, skal der tages en ny tablet.
English: On days of haemodialysis, Descovy should be administered after completion of haemodialysis treatment.
Danish: På dage med hæmodialyse, skal Descovy administreres efter fuldført hæmodialysebehandling.
English: Animal studies do not indicate direct or indirect harmful effects of emtricitabine with respect to fertility parameters, pregnancy, foetal development, parturition or postnatal development.
Danish: Dyrestudier indikerer hverken direkte eller indirekte skadelige virkninger af emtricitabin hvad angår fertilitetsparametre, graviditet, føtal udvikling, fødsel og postnatal udvikling.
English: Of the 62 patients who were HBV suppressed at baseline, 59 remained suppressed and
Danish: Ud af de 62 patienter, som var HBV-supprimerede ved baseline, forblev 59 supprimerede, og 3 havde manglende data.
English: Through 144 weeks of treatment, no subject discontinued E/C/F/TAF due to a treatment-emergent renal adverse event compared with 12 subjects who discontinued E/C/F/TDF (p < 0.001).
Danish: Til og med 144 ugers behandling fik ingen forsøgspersoner seponeret E/C/F/TAF på grund af behandlingsrelaterede renale bivirkninger, sammenlignet med 12 forsøgspersoner, der fik seponeret E/C/F/TDF (p < 0,001).
English: In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 μg/mL.
Danish: Emtricitabins binding in vitro til humane plasmaproteiner var < 4 % og uafhængig af koncentrationsområdet på 0,02-200 µg/ml.
English: There are no data available to make dosing recommendations for co-administration with other protease inhibitors.
Danish: Der foreligger ingen data til at give doseringsanbefalinger ved samtidig administration med andre proteasehæmmere.
English: Co-administration with Descovy is not recommended.
Danish: Samtidig administration med Descovy anbefales ikke.
English: No dose adjustment of sofosbuvir, velpatasvir or voxilaprevir is required.
Danish: Dosisjustering af sofosbuvir, velpatasvir eller voxilaprevir er ikke nødvendig.
English: Patients were randomised in a 1:1 ratio to either switch to Descovy (n = 333), or stay on their baseline emtricitabine/tenofovir disoproxil fumarate containing regimen (n = 330).
Danish: Patienterne blev randomiseret i forholdet 1:1 enten til et skift til Descovy (n = 333) eller blev på deres regime indeholdende emtricitabin/tenofovirdisoproxilfumarat ved baseline (n = 330).
English: b In both studies, patients were stratified by baseline HIV-1 RNA (≤ 100,000 copies/mL, > 100,000 copies/mL to ≤ 400,000 copies/mL, or > 400,000 copies/mL), by CD4+ cell count (< 50 cells/μL, 50-199 cells/μL, or ≥ 200 cells/μL), and by region (US or ex-US).
Danish: b I begge studier blev patienterne stratificeret ved baseline hiv 1-rna (≤ 100.000 kopier/ml, > 100.000 kopier/ml til ≤ 400.000 kopier/ml eller > 400.000 kopier/ml) ved CD4+ celletal (< 50 celler/μl, 50-199 celler/μl eller ≥ 200 celler/μl), og ved region (USA eller uden for USA).
English: Descovy may interact with other medicines.
Danish: Descovy kan påvirke eller påvirkes af anden medicin.
English: Tenofovir alafenamide is not an inhibitor of human uridine diphosphate glucuronosyltransferase (UGT) 1A1 in vitro.
Danish: Tenofoviralafenamid er ikke en hæmmer af humant uridindiphosphat-glucoronosyltransferase (UGT) 1A1 in vitro.
English: Descovy should be avoided in antiretroviral-experienced patients with HIV-1 harbouring the K65R mutation (see section 5.1).
Danish: Descovy bør undgås hos behandlingserfarne patienter, hvor hiv 1 indeholder K65R-mutationen (se pkt.
English: Of the patients who were HBsAg positive at baseline, 3/70 (4.3%) achieved seroconversion to anti-HBs Week 48.
Danish: Ud af de patienter, som var HBsAg-positive ved baseline, opnåede 3/70 (4,3 %) serokonvertering til anti-HBs ved uge 48.
English: Because there is a lower tenofovir exposure in rats and mice after the administration of tenofovir alafenamide compared to tenofovir disoproxil fumarate, carcinogenicity studies and a rat peripostnatal study were conducted only with tenofovir disoproxil fumarate.
Danish: Da der er en lavere eksponering for tenofovir hos rotter og mus efter administration af tenofoviralafenamid sammenlignet med tenofovirdisoproxilfumarat, blev der kun udført karcinogenicitetsstudier og et peri-postnatalt studie hos rotter med tenofovirdisoproxilfumarat.
English: Tenofovir alafenamide is permeable into cells and due to increased plasma stability and intracellular activation through hydrolysis by cathepsin A, tenofovir alafenamide is more efficient than tenofovir disoproxil fumarate in concentrating tenofovir in peripheral blood mononuclear cells (PBMCs) or HIV target cells including lymphocytes and macrophages.
Danish: Tenofoviralafenamid er permeabelt i cellerne, og som følge af en øget plasmastabilitet og intracellulær aktivering via hydrolyse af cathepsin A er tenofoviralafenamid mere effektivt end tenofovirdisoproxilfumarat til at koncentrere tenofovir i perifere mononukleære blodceller (PBMC'er, peripheral blood mononuclear cells) eller hiv-målceller, herunder lymfocytter og makrofager.
English: Other medicines and Descovy Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Danish: Brug af anden medicin sammen med Descovy Fortæl altid lægen eller apotekspersonalet, hvis De tager anden medicin eller har gjort det for nylig.
English: At the start of treatment with E/C/F/TAF, the 72 patients had been HIV-suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months with or without suppression of HBV DNA and had compensated liver function.
Danish: Ved starten af behandlingen med E/C/F/TAF havde 72 patienter været hiv-supprimerede (hiv-1 RNA < 50 kopier/ml) i mindst 6 måneder med eller uden supprimering af HBV DNA, og de havde kompenseret leverfunktion.
English: Co-administration of Descovy and oxcarbazepine, phenobarbital or phenytoin is not recommended.
Danish: Samtidig administration af Descovy og oxcarbazepin, phenobarbital eller phenytoin anbefales ikke.
English: Eighty-six percent of patients (62/72) were HBV suppressed (HBV DNA < 29 IU/mL) and 42% (30/72) were HBeAg positive at baseline.
Danish: 86 procent af patienterne (62/72) var HBV-supprimerede (HBV DNA < 29 IE/ml), og 42 %(30/72) var HBeAg-positive ved baseline.
English: Patients with HIV-1 harbouring mutations
Danish: Patienter med hiv 1, der indeholder mutationer
English: Patients must have been stably suppressed (HIV-1 RNA < 50 copies/mL) on their baseline regimen for at least 6 months and had HIV-1 with no resistance mutations to emtricitabine or tenofovir alafenamide prior to study entry.
Danish: Patienterne skal have haft stabil supprimering (hiv 1-rna < 50 kopier/ml) i deres regime ved baseline i mindst 6 måneder og have hiv 1 uden resistensmutationer for emtricitabin eller tenofoviralafenamid, før de indgik i studiet.
English: No dose adjustment of Descovy is required in adults or adolescents (aged at least 12 years and of at least 35 kg body weight) with estimated creatinine clearance (CrCl) ≥ 30 mL/min.
Danish: Dosisjustering af Descovy er ikke nødvendig hos voksne og unge (i alderen mindst 12 år og med en legemsvægt på mindst 35 kg) med en estimeret kreatininclearance (CrCl) ≥ 30 ml/min.
English: Table 5: Virological outcomes of Study GS-US-299-0102 at Week 24 and 48a
Danish: Tabel 5: Virologiske resultater af studie GS-US-299-0102 ved uge 24 og 48a
English: • herbal remedies used to treat depression and anxiety containing: St. John's wort (Hypericum perforatum)
Danish: • naturlægemidler, der anvendes til at behandle depression og angst, og indeholder: Perikon (Hypericum perforatum)
English: Following multiple dose oral administration of emtricitabine to 20 HIV-1 infected subjects, the (mean ± SD) steady state plasma emtricitabine peak concentrations (Cmax) were 1.8 ± 0.7 μg/mL and the area-under the plasma concentration-time curve over a 24-hour dosing interval (AUC) was 10.0 ± 3.1 μg•h/mL.
Danish: Efter administration af flere orale doser af emtricitabin til 20 hiv 1-inficerede personer, var (gennemsnit ± SD) steady-state maksimale plasmakoncentrationer af emtricitabin (Cmax) 1,8 ± 0,7 μg/ml og arealet under tidskurven for plasmakoncentrationen over et 24-timers doseringsinterval (AUC) var 10,0 ± 3,1 μg•t/ml.
English: High density polyethylene (HDPE) bottle with a polypropylene continuous-thread, child-resistant cap, lined with an induction activated aluminium foil liner containing 30 film-coated tablets.
Danish: Højdensitets-polyethylen (HDPE)-beholder med børnesikret skruelåg af polypropylen foret med induktionsaktiveret aluminiumsfolie indeholdende 30 filmovertrukne tabletter.
English: In the E/C/F/TAF group, the mutations that emerged were M184V/I (n = 11) and K65R/N (n = 2) in RT and T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1), and N155H (n = 2) in integrase.
Danish: I gruppen med E/C/F/TAF var de mutationer, der opstod, M184V/I (n = 11) og K65R/N (n = 2) i RT og T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1) og N155H (n = 2) i integrase.
English: Baseline CD4+ cell count < 200 cells/mm3
Danish: CD4+ celletal ved baseline < 200 celler/mm3
English: D/C/F/TAF = darunavir/cobicistat/emtricitabine/tenofovir alafenamide a Week 48 window was between Day 294 and 377 (inclusive).
Danish: D/C/F/TAF = darunavir/cobicistat/emtricitabin/tenofoviralafenamid a Uge 48-vinduet var fra dag 294 til 377 (inklusive).
English: In vitro binding of tenofovir to human plasma proteins is < 0.7% and is independent of concentration over the range of 0.01-25 μg/mL.
Danish: Tenofovirs binding in vitro til humane plasmaproteiner er < 0,7 % og uafhængig af koncentrationsområdet på 0,01-25 μg/ml.
English: Film-coating: Polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, indigo carmine aluminium lake (E132).
Danish: Filmovertræk: Polyvinylalkohol, titandioxid, macrogol 3350, talcum, indigocarmin aluminiumpigment (E132).
English: The median (Q1, Q3) change from baseline in total cholesterol to HDL-cholesterol ratio at Week 144 was 0.2 (-0.3, 0.7) in the E/C/F/TAF group and 0.1 (-0.4, 0.6) in the E/C/F/TDF group (p = 0.006 for the difference between treatment groups).
Danish: Den mediane (Q1, Q3) ændring fra baseline i forholdet mellem total kolesterol og HDL-kolesterol ved uge 144 var 0,2 (-0,3; 0,7) i gruppen med E/C/F/TAF og 0,1 (-0,4; 0,6) i gruppen med E/C/F/TDF (p = 0,006 for forskellen mellem behandlingsgrupperne).
English: At baseline, 30% of patients were receiving abacavir/lamivudine in combination with a boosted protease inhibitor and 70% of patients were receiving abacavir/lamivudine in combination with an unboosted third agent.
Danish: Ved baseline fik 30 % af patienter abacavir/lamivudin i kombination med en boosted PI og 70 % af patienterne fik abacavir/lamivudin i kombination med et ikke boosted tredje stof.
English: c Includes patients who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window.
Danish: c Omfatter patienter, som afbrød behandlingen som følge af en AE eller død på et tidspunkt fra dag 1 og i løbet af tidsvinduet, hvis dette ikke resulterede i virologiske data om behandlingen i løbet af det specificerede tidsvindue.
English: Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 in vitro.
Danish: Tenofoviralafenamid er ikke en hæmmer af CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 eller CYP2D6 in vitro.
English: Co-administration of Descovy with other medicinal products that inhibit P-gp and BCRP activity (e.g., cobicistat, ritonavir, ciclosporin) is expected to increase the absorption and plasma concentration of tenofovir alafenamide.
Danish: Samtidig administration af Descovy med andre lægemidler, der hæmmer P-gp- og BCRP-aktiviteten (f.eks. cobicistat, ritonavir, ciclosporin) forventes at øge absorptionen og plasmakoncentrationen af tenofoviralafenamid.
English: Descovy should generally be avoided but may be used in adults with end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis if the potential benefits outweigh the potential risks (see section 4.2).
Danish: Descovy bør generelt undgås, men kan anvendes hos voksne med nyresygdom i slutstadiet (estimeret CrCl < 15 ml/min) i kronisk hæmodialyse, hvis de potentielle fordele opvejer de potentielle risici (se pkt.
English: Hepatic impairment No dose adjustment of Descovy is required in patients with hepatic impairment.
Danish: Nedsat leverfunktion Dosisjustering af Descovy er ikke nødvendig hos patienter med nedsat leverfunktion.
English: Emtricitabine displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC50 values ranged from 0.007 to 0.075 μM) and showed strain specific activity against HIV-2 (EC50 values ranged from 0.007 to 1.5 μM).
Danish: Emtricitabin viste antiviral aktivitet i cellekultur mod hiv 1-kladerne A, B, C, D, E, F og G (EC50-værdier var i intervallet fra 0,007 til 0,075 µM) og viste stammespecifik aktivitet mod hiv 2 (EC50-værdier var i intervallet fra 0,007 til 1,5 µM).
English: Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1) (see sections 4.2 and 5.1).
Danish: Descovy er indiceret i kombination med andre antiretrovirale stoffer til behandling af voksne og unge (i alderen 12 år og ældre, med en legemsvægt på mindst 35 kg), som er inficerede med humant immundefekt virus type 1 (hiv 1) (se pkt.
English: Co-administration of Descovy and carbamazepine is not recommended.
Danish: Samtidig administration af Descovy og carbamazepin anbefales ikke.
English: E/C/F/TAF = elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate FTC = emtricitabine; TAF = tenofovir alafenamide fumarate; TFV = tenofovir N/A = not applicable
Danish: E/C/F/TAF = elvitegravir/cobicistat/emtricitabin/tenofoviralafenamidfumarat FTC = emtricitabin, TAF = tenofoviralafenamidfumarat, TFV = tenofovir Data vises som gennemsnit (% CV).
English: In Study GS-US-311-1717, patients who were virologically suppressed (HIV-1 RNA <50 copies/mL) on their abacavir/lamivudine containing regimen for at least 6 months were randomised in a 1:1 ratio to either switch to Descovy (N=280) while maintaining their third agent at baseline or stay on their baseline abacavir/lamivudine -containing regimen (N=276).
Danish: I studie GS-US-311-1717 blev patienter, som var virologisk supprimerede (hiv 1-rna < 50 kopier/ml) i deres regime indeholdende abacavir/lamivudin i mindst 6 måneder, randomiseret i forholdet 1:1 enten til et skift til Descovy (n = 280), mens de fortsatte med det tredje stof ved baseline eller blev på deres baseline regime indeholdende abacavir/lamivudin (n = 276).
English: Co-administration of Descovy and rifabutin rifampicin, or rifapentine is not recommended.
Danish: Samtidig administration af Descovy og rifabutin, rifampicin eller rifapentin anbefales ikke.
English: It is not known whether tenofovir alafenamide is excreted in human milk.
Danish: Det er ukendt, om tenofoviralafenamid udskilles i human mælk.
English: The active substances are emtricitabine and tenofovir alafenamide.
Danish: Aktive stoffer: emtricitabin og tenofoviralafenamid.
English: In animal studies there were no effects of emtricitabine and tenofovir alafenamide on mating or fertility parameters (see section 5.3).
Danish: I dyrestudier var der ingen virkning af emtricitabin og tenofoviralafenamid på parrings- eller fertilitetsparametre (se pkt.
English: Patients co-infected with HIV and HBV
Danish: Patienter med samtidig infektion med hiv og HBV
English: Tenofovir has activity against HIV-1, HIV-2, and HBV.
Danish: Tenofovir har aktivitet mod hiv 1-, hiv 2- og HBV.
English: Interaction not studied with either of the components of Descovy.
Danish: Interaktion er ikke undersøgt med nogen af Descovys komponenter.
English: At baseline, 46% of patients were receiving emtricitabine/tenofovir disoproxil fumarate in combination with a boosted PI and 54% of patients were receiving emtricitabine/tenofovir disoproxil fumarate in combination with an unboosted third agent.
Danish: Ved baseline fik 46 % af patienter emtricitabin/tenofovirdisoproxilfumarat i kombination med en boosted PI og 54 % af patienterne fik emtricitabin/tenofovirdisoproxilfumarat i kombination med et ikke boosted tredje stof.
English: At 48 weeks, 92% (46/50) achieved HIV-1 RNA < 50 copies/mL, similar to response rates in studies of treatment-naïve HIV-1 infected adults.
Danish: 92 % (46/50) opnåede hiv 1-rna < 50 kopier/ml ved 48 uger, hvilket er sammenligneligt med responsrater i studier af behandlingsnaive hiv 1-inficerede voksne.
English: angioedema3, 4, pruritus, urticaria4 Musculoskeletal and connective tissue disorders Uncommon:
Danish: angioødem3, 4, pruritus, urticaria4 Knogler, led, muskler og bindevæv Ikke almindelig:
English: The co-administration of Descovy is not recommended with certain anticonvulsants (e.g., carbamazepine, oxcarbazepine, phenobarbital and phenytoin), antimycobacterials (e.g., rifampicin, rifabutin, rifapentine), St. John's wort and HIV protease inhibitors (PIs) other than atazanavir, lopinavir and darunavir (see section 4.5).
Danish: Den samtidige administration af Descovy anbefales ikke sammen med visse antikonvulsiva (f.eks. carbamazepin, oxcarbazepin, phenobarbital og phenytoin), antimykobakterielle lægemidler (f.eks. rifampicin, rifabutin, rifapentin), prikbladet perikum og andre hiv proteasehæmmere (PI'er) end atazanavir, lopinavir og darunavir (se pkt.
English: Emtricitabine triphosphate inhibits HIV replication through incorporation into viral deoxyribonucleic acid (DNA) by the HIV reverse transcriptase (RT), which results in DNA chaintermination.
Danish: Emtricitabintriphosphat hæmmer hiv-replikation via indbygning i viralt deoxyribonukleinsyre (dna) af hiv-revers transkriptase (RT), hvilket resulterer i dna-kædeblokering.
English: The median increase from baseline for those parameters was greater in the E/C/F/TAF group compared with the elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg (E/C/F/TDF) group at Week 144 (p < 0.001 for the difference between treatment groups for fasting total cholesterol, direct LDL- and HDL-cholesterol, and triglycerides).
Danish: Den mediane stigning fra baseline for disse parametre var større i gruppen med E/C/F/TAF sammenlignet med gruppen med elvitegravir 150 mg/cobicistat 150 mg/emtricitabin 200 mg/tenofovirdisoproxil (som fumarat) 245 mg (E/C/F/TDF) ved uge 144 (p < 0,001 for forskellen mellem behandlingsgrupperne for fastende total kolesterol, direkte LDL- og HDL-kolesterol samt triglycerider).
English: Discontinuation of Descovy therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis.
Danish: Seponering af behandlingen med Descovy hos patienter, som samtidig er inficerede med hiv og HBV, kan forekomme i forbindelse med svær, akut eksacerbation af hepatitis.
English: Clinical efficacy of Descovy in treatment-naïve patients was also established from a study conducted with emtricitabine and tenofovir alafenamide (10 mg) when given with darunavir (800 mg) and cobicistat as a fixed-dose combination tablet (D/C/F/TAF).
Danish: Den kliniske virkning af Descovy hos behandlingsnaive patienter blev også klarlagt fra et studie udført med emtricitabin og tenofoviralafenamid (10 mg), når det blev givet sammen med darunavir (800 mg) og cobicistat som en fastdosis kombinationstablet (D/C/F/TAF).
English: Film-coating: Polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, iron oxide black (E172).
Danish: Filmovertræk: Polyvinylalkohol, titandioxid, macrogol 3350, talcum, jernoxid, sort (E172).
English: Co-administration of fluconazole or isavuconazole may increase plasma concentrations of tenofovir alafenamide.
Danish: Samtidig administration af fluconazol eller isavuconazol kan øge plasmakoncentrationerne af tenofoviralafenamid.